Table of Content - Global Imaging CRO Market

res
Imaging CRO
Market -
A Global and
Regional Analysis
Table of Content
Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/
Focus on Services, Modalities,

Applications, Phases, End User, Country
Data (11 Countries), and Competitive
Global Imaging CRO Market
Landscape
Analysis and Forecast: 2020-2031
September 2021
All rights reserved at BIS Research Inc.

BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2021 BIS Research Inc.

All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

Table of Content
Executive Summary .......................................................................... 15
Research Methodology ..................................................................... 19
1. Market Overview ........................................................................ 23

1.1 Market Definition.............................................................................................. 24
1.2 Global Imaging CRO Market Footprint ........................................................... 24
1.3 Realistic and Optimistic View of Global Imaging CRO Market, $Million,
2020-2031.......................................................................................................... 25
1.4 Current Imaging CRO Landscape .................................................................. 26
2. Industry Analysis ....................................................................... 28

2.1 Regulatory Framework in the U.S. ................................................................. 29
2.1.1 Imaging CRO Workflow............................................................................... 29
2.2 Regulatory Framework in Europe .................................................................. 30
2.3 Regulatory Framework in Asia-Pacific Countries ......................................... 30
2.3.1 China ............................................................................................................ 30
2.3.2 Japan ............................................................................................................ 31
3. Market Dynamics ....................................................................... 32

3.1 Market Dynamics ............................................................................................. 33
3.1.1 Drivers .......................................................................................................... 33
3.1.1.1 Continued Growth in R&D Spending ................................................................. 33
3.1.1.2 Increase in the Annual Number of Clinical Trials with Medical Imaging ............ 34
3.1.2 Restraints ..................................................................................................... 35

3.1.2.1 High Installation Cost of Medical Imaging Systems ........................................... 35
3.1.2.2 Supply Chain and Logistical Challenges ........................................................... 35
3.1.3 Opportunities ............................................................................................... 36
3.1.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies .................. 36
3.1.3.2 Automation in Imaging CRO Process ................................................................ 36

3

4. Competitive Landscape............................................................. 38
4.1 Overview ........................................................................................................... 39
4.2 Synergistic Activities ...................................................................................... 40
4.2.1 Mergers and Acquisitions ........................................................................... 41
4.2.2 New Service Launch.................................................................................... 41
4.2.3 Expansion .................................................................................................... 41
4.3 Market Share Analysis, By Company ............................................................. 42
4.4 Growth Share Analysis, By Company ............................................................ 43
5. Services, $Million, 2020-2031 .................................................... 45

5.1 Overview ........................................................................................................... 46
5.1.1 Imaging Acquisition and Protocol Development ...................................... 47
5.1.2 Application Design ...................................................................................... 48
5.1.3 Image Collection and QC ............................................................................ 48
5.1.4 Digital Image Conversion ........................................................................... 49
5.1.5 Support and Maintenance ........................................................................... 50
6. Modalities, $Million, 2020-2031.................................................. 51

6.1 Overview ........................................................................................................... 52
6.1.1 Computed Tomography (CT) Scan ............................................................ 52
6.1.2 Magnetic Resonance Imaging (MRI) .......................................................... 53
6.1.2.1 Diffusion Tensor Imaging (DTI) .......................................................................... 54
6.1.2.2 Functional MRI (fMRI) ........................................................................................ 55
6.1.2.3 Resting-State Functional Connectivity MRI (fcMRI) .......................................... 55

6.1.2.4 Volumetric MRI (vMRI) ...................................................................................... 56
6.1.2.5 Arterial Spin Labeling for Quantitative Perfusion Imaging (ASL) ....................... 57
6.1.3 Positron Emission Tomography (PET) ...................................................... 57
6.1.3.1 Positron Emission Tomography with 18F Isotope (FDG-PET) .......................... 58
6.1.3.2 Other PET .......................................................................................................... 59

6.1.4 Other Modalities .......................................................................................... 59
6.1.4.1 X-Rays ............................................................................................................... 60
6.1.4.2 Ultrasound ......................................................................................................... 61
6.1.4.3 Scanning Laser Ophthalmoscopy (SLO) ........................................................... 61
6.1.4.4 Optical Coherence Tomography ........................................................................ 62
6.1.4.5 Scanning Laser Polarimetry (SLP) .................................................................... 63
6.1.4.6 Others ................................................................................................................ 63
7. Clinical Trial Phase, $Million, 2020-2031 .................................... 65

7.1 Overview ........................................................................................................... 66
7.1.1 Phase I .......................................................................................................... 67
7.1.2 Phase II ......................................................................................................... 68
7.1.3 Phase III ........................................................................................................ 68
8. Applications, $Million, 2020-2031 ............................................... 70

8.1 Overview ........................................................................................................... 71
8.1.1 Oncology Imaging CRO .............................................................................. 72
8.1.2 Ophthalmology Imaging CRO..................................................................... 73
8.1.3 Neurology Imaging CRO ............................................................................. 74
8.1.4 Cardiology Imaging CRO ............................................................................ 75
8.1.5 Other Applications ...................................................................................... 76
9. End-User, $Million, 2020-2031 .................................................... 77

9.1 Overview ........................................................................................................... 78
9.1.1 Pharmaceutical Companies ........................................................................ 79
9.1.2 Biotechnology Companies ......................................................................... 79

9.1.3 Medical Device Manufacturers ................................................................... 80
9.1.4 Contract Research Organizations (CRO) .................................................. 81
9.1.5 Academic and Government Research Institutes ...................................... 82
9.1.6 Other End Users .......................................................................................... 82

10. Regions, $Million, 2020-2031 ..................................................... 84
10.1 Overview ........................................................................................................... 85
10.2 North America .................................................................................................. 87
10.2.1 U.S. ............................................................................................................... 89
10.2.2 Canada ......................................................................................................... 90
10.3 Europe .............................................................................................................. 92
10.3.1 Germany ....................................................................................................... 93
10.3.2 U.K. ............................................................................................................... 94
10.3.3 France........................................................................................................... 95
10.3.4 Italy ............................................................................................................... 96
10.3.5 Spain............................................................................................................. 97
10.3.6 Rest-of-Europe............................................................................................. 98
10.4 Asia-Pacific .................................................................................................... 100
10.4.1 China .......................................................................................................... 101
10.4.2 India ............................................................................................................ 103
10.4.3 Japan .......................................................................................................... 104
10.4.4 Australia ..................................................................................................... 105
10.4.5 Rest-of-Asia-Pacific................................................................................... 106
10.5 Rest-of-the-World .......................................................................................... 107
11. Company Profile ...................................................................... 108

11.1 Overview ......................................................................................................... 109
11.2 Worldcare Clinical, LLC ................................................................................ 110

11.2.1 Company Overview ................................................................................... 110
11.2.2 Role of Worldcare Clinical, LLC in the Global Imaging CRO Market .... 110
11.2.3 SWOT Analysis .......................................................................................... 112
11.3 LabCorp Drug Development (Laboratory Corporation of America

Holdings) ........................................................................................................ 113

11.3.2 Role of LabCorp Drug Development in the Global Imaging CRO

Market ......................................................................................................... 113
11.3.3 Financials ................................................................................................... 114
11.3.4 SWOT Analysis .......................................................................................... 116
11.4 IXICO PLC ....................................................................................................... 117
11.4.2 Financials ................................................................................................... 118
11.4.3 SWOT Analysis .......................................................................................... 119
11.5 ICON plc.......................................................................................................... 120
11.5.2 Role of ICON plc in the Global Imaging CRO Market ............................. 120
11.5.3 Financials ................................................................................................... 121
11.5.4 SWOT Analysis .......................................................................................... 122
11.6 The Micron Group .......................................................................................... 123
11.6.2 SWOT Analysis .......................................................................................... 124
11.7 Medpace Holdings, Inc. ................................................................................. 125
11.7.2 Financials ................................................................................................... 126
11.7.3 SWOT Analysis .......................................................................................... 127
11.8 Radiant Sage LLC .......................................................................................... 128

11.8.2 SWOT Analysis .......................................................................................... 129
11.9 Biomedical Systems Corporation (ERT) ...................................................... 130
11.9.2 SWOT Analysis .......................................................................................... 131

11.10 Bioclinica ........................................................................................................ 132
11.10.1 Company Overview ............................................................................. 132
11.10.2 SWOT Analysis.................................................................................... 133
11.11 Imaging Endpoints LLC ................................................................................ 134
11.11.2 Role of Imaging Endpoints LLC in the Global Imaging CRO

Market ......................................................................................................... 134
11.11.3 SWOT Analysis.................................................................................... 135
11.12 Parexel International Corporation ................................................................ 136
11.12.2 Role of Parexel International Corporation in the Global Imaging

CRO Market ................................................................................................ 136
11.12.3 SWOT Analysis.................................................................................... 138
11.13 Wuxi AppTec .................................................................................................. 139
11.13.2 Role of Wuxi AppTec in the Global Imaging CRO Market ............... 139
11.13.3 Financials ............................................................................................ 141
11.13.4 Key Insights About Financial Health of the Company ..................... 142
11.13.5 SWOT Analysis.................................................................................... 143
11.14 Syneos Health, Inc. ........................................................................................ 144
11.14.2 Role of Syneos Health, Inc. in the Global Imaging CRO Market ..... 144
11.14.3 Financials ............................................................................................ 146

11.14.4 SWOT Analysis.................................................................................... 147

List of Figures
Figure 1: Global Imaging CRO Market, Realistic and Optimistic Scenario, $Million, 2020-2031
Figure 2: Global Imaging CRO Market Dynamics
Figure 3: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 4: Growth Share Matrix for Global Imaging CRO Market (by Company), 2019- 2020
Figure 5: Global Imaging CRO Market Research Methodology
Figure 6: Primary Research Methodology
Figure 7: Global Imaging CRO Market, $Million, 2020-2031
Figure 8: Realistic and Optimistic View of Global Imaging CRO Market, $Million, 2020-2031
Figure 9: Overview of CRO and Contract Development and Manufacturing Organization (CDMO)
Drug Development Services
Figure 10: Global Imaging CRO Market Dynamics
Figure 11: Share of Key Market Strategies and Developments, July 2017-July 2021
Figure 12: Share of Synergistic Activities (by Company), July 2017- July 2021
Figure 13: Share of Mergers and Acquisitions (by Company), July 2017-July 2021
Figure 14: Market Share Analysis for Global Imaging CRO Market, 2019 and 2020
Figure 15: Growth Share Matrix for Global Imaging CRO Market (by Company), 2019 and 2020
Figure 16: Global Imaging CRO Market (by Service)
Figure 17: Share of Global Imaging CRO Market (by Service), 2020 and 2031
Figure 18: Imaging Acquisition and Protocol Development Market Size and Forecast, $Million, 2020-
2031
Figure 19: Application Design Market Size and Forecast, $Million, 2020-2031
Figure 20: Image Collection and QC Market Size and Forecast, $Million, 2020-2031
Figure 21: Digital Image Conversion Market Size and Forecast, $Million, 2020-2031
Figure 22: Support and Maintenance Market Size and Forecast, $Million, 2020-2031
Figure 23: Share of Global Imaging CRO Market (by Modality), $Million, 2020 and 2031
Figure 24: Global Imaging CRO Market (by Computed Tomography (CT) Scan), $Million, 2020-2031
Figure 25: Global Imaging CRO Market (by Magnetic Resonance Imaging (MRI)) $Million, 2020-2031
Figure 26: Global Imaging CRO Market (by Diffusion Tensor Imaging (DTI)), $Million, 2020-2031
Figure 27: Global Imaging CRO Market (by Functional MRI (fMRI)), $Million, 2020-2031
Figure 28: Global Imaging CRO Market (by Resting-State Functional Connectivity MRI (fcMRI)),
$Million, 2020-2031
Figure 29: Global Imaging CRO Market (by Volumetric MRI (vMRI)), $Million, 2020-2031
Figure 30: Global Imaging CRO Market (by Arterial Spin Labeling (ASL)), $Million, 2020-2031
Figure 31: Global Imaging CRO Market (by Positron Emission Tomography (PET)), $Million, 2020-
2031
Figure 32: Global Imaging CRO Market (by Positron Emission Tomography with 18F Isotope (FDG-
PET)), $Million, 2020-2031

Figure 33: Global Imaging CRO Market (by Other PET), $Million, 2020-2031
Figure 34: Global Imaging CRO Market (by Positron Emission Tomography (PET)), $Million, 2020-
2031
Figure 35: Global Imaging CRO Market (by X-Ray), $Million, 2020-2031
Figure 36: Global Imaging CRO Market (by Ultrasound), $Million, 2020-2031
Figure 37: Global Imaging CRO Market (by Scanning Laser Ophthalmoscopy (SLO)), $Million, 2020-
2031
Figure 38: Global Imaging CRO Market (Optical Coherence Tomography), $Million, 2020-2031
Figure 39: Global Imaging CRO Market (by Scanning Laser Polarimetry (SLP)), $Million, 2020-2031
Figure 40: Global Imaging CRO Market (by Others), $Million, 2020-2031
Figure 41: Global Imaging CRO Market (by End User), $Million, 2020 and 2031
Figure 42: Global Imaging CRO Market (by Phase I), $Million, 2020-2031
Figure 43: Global Imaging CRO Market (by Phase II), $Million, 2020-2031
Figure 44: Global Imaging CRO Market (by Phase III), $Million, 2020-2031
Figure 45: Global Imaging CRO Market (by Application)
Figure 46: Share of Global Imaging CRO Market (by Application), $Million, 2020 and 2031
Figure 47: Global Imaging CRO Market, (by Oncology Imaging CRO), $Million, 2020-2031
Figure 48: Global Imaging CRO Market, (by Ophthalmology Imaging CRO), $Million, 2020-2031
Figure 49: Global Imaging CRO Market, (by Neurology Imaging CRO), $Million, 2020-2031
Figure 50: Global Imaging CRO Market, (by Cardiology Imaging CRO), $Million, 2020-2031
Figure 51: Global Imaging CRO Market, (by Other Applications), $Million, 2020-2031
Figure 52: Global Imaging CRO Market (by End User), $Million, 2020 and 2031
Figure 53: Global Imaging CRO Market, (by Pharmaceutical Companies), $Million, 2020-2031
Figure 54: Global Imaging CRO Market, (by Biotechnology Companies), $Million, 2020-2031
Figure 55: Global Imaging CRO Market, (by Medical Device Manufacturers), $Million, 2020-2031
Figure 56: Global Imaging CRO Market, (by Contract Research Organizations (CRO)), $Million, 2020-
2031
Figure 57: Global Imaging CRO Market, (by Academic and Government Research Institutes), $Million,
2020-2031
Figure 58: Global Imaging CRO Market, (by Other End Users), $Million, 2020-2031
Figure 59: Global Imaging CRO Market (by Region), $Million, 2020
Figure 60: Share of North America Imaging CRO Market Revenue (by Country), $Million, 2020-2031
Figure 61: North America: Market Dynamics
Figure 62: U.S. Imaging CRO Market, $Million, 2020-2031

Figure 63: Canada Imaging CRO Market, $Million, 2020-2031
Figure 64: Share of Europe Imaging CRO Market (by Country), $Million, 2020-2031
Figure 65: Europe: Market Dynamics
Figure 66: Germany Imaging CRO Market Revenue, $Million, 2020-2031
Figure 67: U.K. Imaging CRO Market Revenue, $Million, 2020-2031
10

Figure 68: France Imaging CRO Market Revenue, $Million, 2020-2031
Figure 69: Italy Imaging CRO Market Revenue, $Million, 2020-2031
Figure 70: Spain Imaging CRO Market Revenue, $Million, 2020-2031
Figure 71: Rest-of-Europe Imaging CRO Market Revenue, $Million, 2020-2031
Figure 72: Asia-Pacific: Market Dynamics
Figure 73: Asia-Pacific Imaging CRO Market Revenue (by Country), $Million, 2020-2031,
Figure 74: China Imaging CRO Market Revenue, $Million, 2020-2031
Figure 75: India Imaging CRO Market Revenue, $Million, 2020-2031
Figure 76: Japan Imaging CRO Market Revenue, $Million, 2020-2031
Figure 77: Australia Imaging CRO Market Revenue, $Million, 2020-2031
Figure 78: Rest-of-Asia-Pacific Imaging CRO Market Revenue, $Million, 2020-2031
Figure 79: Rest-of-the-World Imaging CRO Market Revenue, $Million, 2020-2031
Figure 80: Total Number of Companies Profiled
Figure 81: Worldcare Clinical, LLC: Overall Service Portfolio
Figure 82: Worldcare Clinical: SWOT Analysis
Figure 83: LabCorp Drug Development: Overall Service Portfolio
Figure 84: LabCorp Drug Development: Overall Financials, 2018-2020
Figure 85: LabCorp Drug Development: Net Revenue (by Business Segment), 2018-2020
Figure 86: LabCorp Drug Development: Net Revenue (by Region), 2018-2020
Figure 87: LabCorp Drug Development: SWOT Analysis
Figure 88: IXICO PLC: Overall Service Portfolio
Figure 89: IXICO PLC: Overall Financials, 2018-2020
Figure 90: IXICO PLC: Net Revenue (by Region), 2018-2020
Figure 91: IXICO PLC: SWOT Analysis
Figure 92: ICON plc: Overall Service Portfolio
Figure 93: ICON plc: Overall Financials, 2018-2020
Figure 94: ICON plc: Revenue (by Region), 2018-2020
Figure 95: ICON plc: SWOT Analysis
Figure 96: The Micron Group.: Overall Service Portfolio
Figure 97: The Micron Group: SWOT Analysis
Figure 98: Medpace Holdings, Inc.: Overall Service Portfolio
Figure 99: Medpace Holdings, Inc.: Overall Financials, 2018-2020
Figure 100: Medpace Holdings, Inc.: Net Revenue (by Therapeutic Area), 2018-2020
Figure 101: Medpace Holdings, Inc.: SWOT Analysis
Figure 102: Radiant Sage LLC: Overall Service Portfolio
Figure 103: Radiant Sage LLC: SWOT Analysis
Figure 104: Biomedical Systems Corporation (ERT): Overall Service Portfolio
Figure 105: Biomedical Systems Corporation (ERT): SWOT Analysis
Figure 106: Bioclinica: Overall Service Portfolio
11

Figure 107: Bioclinica: SWOT Analysis
Figure 108: Imaging Endpoints LLC: Overall Service Portfolio
Figure 109: Imaging Endpoints LLC: SWOT Analysis
Figure 110: Parexel International Corporation: Overall Service Portfolio
Figure 111: Parexel International Corporation: SWOT Analysis
Figure 112: Wuxi AppTec: Overall Service Portfolio
Figure 113: Wuxi AppTec: Overall Financials, 2018-2020
Figure 114: Wuxi AppTec: Revenue (by Segment), 2018-2020
Figure 115: Wuxi AppTec: Revenue (by Region), 2018-2020
Figure 116: Wuxi AppTec: R&D Expenditure, 2018-2020
Figure 117: Wuxi AppTec: SWOT Analysis
Figure 118: Syneos Health, Inc.: Overall Service Portfolio
Figure 119: Syneos Health, Inc.: Overall Financials, 2018-2020
Figure 120: Syneos Health, Inc.: Revenue (by Segment), 2018-2020
Figure 121: Syneos Health, Inc.: Revenue (by Region), 2018-2020
Figure 122: Syneos Health, Inc.: SWOT Analysis
12

List of Tables
Table 1: List of Oncology Related Approvals in 2020
Table 2: Imaging Modalities: Pricing Analysis
13

Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published, or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates, and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties, and contingencies.
For more details regarding permission, please contact us:

Email: sales@bisresearch.com
Tel: +1 510 404 8135
14

BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135

Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
15
www.bisresearch.com

Table of Content - Global Imaging CRO Market

Uploaded by

Copyright:

Available Formats

Table of Content - Global Imaging CRO Market

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Table of Content - Global Imaging CRO Market

Uploaded by

Copyright:

Available Formats

res

Focus on Services, Modalities,

All rights reserved at BIS Research Inc.

Copyright © 2021 BIS Research Inc.

All rights reserved at BIS Research Inc.

Research Methodology ..................................................................... 19

1. Market Overview ........................................................................ 23

1.2 Global Imaging CRO Market Footprint ........................................................... 24

1.4 Current Imaging CRO Landscape .................................................................. 26

2. Industry Analysis ....................................................................... 28

2.1.1 Imaging CRO Workflow............................................................................... 29

2.2 Regulatory Framework in Europe .................................................................. 30

2.3 Regulatory Framework in Asia-Pacific Countries ......................................... 30

2.3.1 China ............................................................................................................ 30

2.3.2 Japan ............................................................................................................ 31

3. Market Dynamics ....................................................................... 32

3.1.1 Drivers .......................................................................................................... 33

3.1.1.1 Continued Growth in R&D Spending ................................................................. 33

3.1.2 Restraints ..................................................................................................... 35

3.1.2.1 High Installation Cost of Medical Imaging Systems ........................................... 35

3.1.2.2 Supply Chain and Logistical Challenges ........................................................... 35

3.1.3 Opportunities ............................................................................................... 36

3.1.3.1 Increasing Outsourcing Trend Among Pharmaceutical Companies .................. 36

3.1.3.2 Automation in Imaging CRO Process ................................................................ 36

All rights reserved at BIS Research Inc.

4.2 Synergistic Activities ...................................................................................... 40

4.2.1 Mergers and Acquisitions ........................................................................... 41

4.2.2 New Service Launch.................................................................................... 41

4.2.3 Expansion .................................................................................................... 41

4.3 Market Share Analysis, By Company ............................................................. 42

4.4 Growth Share Analysis, By Company ............................................................ 43

5. Services, $Million, 2020-2031 .................................................... 45

5.1.1 Imaging Acquisition and Protocol Development ...................................... 47

5.1.2 Application Design ...................................................................................... 48

5.1.3 Image Collection and QC ............................................................................ 48

5.1.4 Digital Image Conversion ........................................................................... 49

5.1.5 Support and Maintenance ........................................................................... 50

6. Modalities, $Million, 2020-2031.................................................. 51

6.1.1 Computed Tomography (CT) Scan ............................................................ 52

6.1.2 Magnetic Resonance Imaging (MRI) .......................................................... 53

6.1.2.1 Diffusion Tensor Imaging (DTI) .......................................................................... 54

6.1.2.2 Functional MRI (fMRI) ........................................................................................ 55

6.1.2.3 Resting-State Functional Connectivity MRI (fcMRI) .......................................... 55

6.1.2.4 Volumetric MRI (vMRI) ...................................................................................... 56

6.1.3 Positron Emission Tomography (PET) ...................................................... 57

6.1.3.1 Positron Emission Tomography with 18F Isotope (FDG-PET) .......................... 58

6.1.3.2 Other PET .......................................................................................................... 59

All rights reserved at BIS Research Inc.

6.1.4.1 X-Rays ............................................................................................................... 60

6.1.4.2 Ultrasound ......................................................................................................... 61

6.1.4.3 Scanning Laser Ophthalmoscopy (SLO) ........................................................... 61

6.1.4.4 Optical Coherence Tomography ........................................................................ 62

6.1.4.5 Scanning Laser Polarimetry (SLP) .................................................................... 63

6.1.4.6 Others ................................................................................................................ 63

7. Clinical Trial Phase, $Million, 2020-2031 .................................... 65

7.1.1 Phase I .......................................................................................................... 67

7.1.2 Phase II ......................................................................................................... 68

7.1.3 Phase III ........................................................................................................ 68

8. Applications, $Million, 2020-2031 ............................................... 70